Skip to main content
OpenTrials
Completed

NCT Number: NCT04690205

Hospital at Home at EOL in Heme Malignancies

This study is evaluating an intervention, which the investigators call "Optimize End of Life (EOL) Care at Home," that entails remote patient monitoring and home-based supportive care for patients with advanced hematologic malignancies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hematologic Malignancy Hematologic Diseases Hematologic Neoplasms Hemic and Lymphatic Diseases Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States

About this study

This research study is a single arm pilot feasibility study, which is the first-time investigators are examining this care at home intervention in patients with advanced hematologic malignancies.

The research study procedures include screening for eligibility, questionnaires, remote patient monitoring (e.g. patient-reported symptoms, home monitored vital signs) and hospital care at home (e.g. providing maximal supportive care to to address and manage patients' symptoms) and structured communications oncology clinicians to optimize end of life care for patients with advanced hematologic malignancies.

Participants will include 3 groups:

  • Enrolled patients with advanced hematologic malignancies receiving the end of life (EOL) care at home intervention; 2) caregivers of these patients; and 3) oncology clinicians caring for these patients.

Participants will be in this research study for approximately six months after consent. It is expected that about 30 patients, 30 caregivers, and 15 oncology clinicians will take part in this research study.

Medically Home company is supporting this research study by providing funding.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 18 or older
  • diagnosed with relapsed or refractory hematologic malignancy
  • must be receiving treatment with non-curative intent or supportive care alone based on the intent of chemotherapy as reported in order entry or Electronic Health Record
  • deemed eligible to receive EOL care at home based on the primary oncologist's assessment
  • Able to communicate and respond to questionnaires in English or with the assistance of an interpreter.
  • residing within 50 miles of MGH. Of note, patients requiring supportive transfusions in the oncology clinic will still be eligible to participate.

Exclusion criteria

  • Those with uncontrolled psychiatric illness or impaired cognition interfering with their ability to understand study procedures and provide written informed consent as determined by the primary oncologist.

Treatment and study plan

End of Life (EOL) Care at at Home

Other

Remote monitoring and home-based care designed for patients with advanced hematologic malignancies

Primary outcomes

  1. Enrollment Rate

    Time frame: 6 months

    The primary endpoint is feasibility. The proposed intervention will be deemed feasible if at least 60% (95% confidence interval +/- 18%) of eligible patients are enrolled in the study.

  2. Retention Rate

    Time frame: 6 months

    The primary endpoint is feasibility. The proposed intervention will be deemed feasible if at least 80% of enrolled participants will complete a minimum of 60% of their daily assessments (i.e. patient-reported symptoms)

Secondary outcomes

  1. Acceptability of the intervention

    Time frame: 6 months

    Qualitative acceptability ratings from patients, caregivers, and oncology clinicians defined by perceptions of usefulness, effectiveness, and relevance of the intervention obtained via interviews regarding acceptability from patients, family caregivers, and oncology clinicians.

  2. Patient Quality of Life (Functional Assessment of Cancer Therapy-General - Fact-G)

    Time frame: up to 6 months

    Change in quality of life as measured by the FACT-G throughout the study. FACT-G score ranges from 0 to 108 points with higher score indicating better quality of life

  3. Caregiver Quality of Life (CareGiver Oncology QOL)

    Time frame: 6 months

    Change in caregiver quality of life as measured by the CarGOQOL throughout the study. Caregiver Oncology QOL questionnaire ranges from 0 to 100 points with higher scores indicating better caregiver quality of life

  4. Patient Symptom Burden (using the Edmonton Symptom Assessment Scale-revise)

    Time frame: up to 6 months

    Change in patient symptom burden measured with Edmonton Symptom Assessment System-revised (ESAS-r). Scores range from 0-100 with higher scores indicate worse symptom burden.

  5. Caregiver Burden

    Time frame: up to 6 months

    Caregiving burden will be assessed using the Caregiver Reaction Assessment (CRA) caregiving burden. The CRA score ranges from 24-120, with higher score indicating higher caregiving burden

  6. Health Care Utilization

    Time frame: 6 months

    Electronic Health Records (EHR) will be used to assess patient health care utilization including hospitalizations, chemotherapy use, and emergency department visits at the end of life.

  7. Patient psychological distress (using the Hospital Anxiety and Depression Scale (HADS))

    Time frame: Up to 6 months

    The Hospital Anxiety and Depression Scale (HADS) will be used to assess patient psychological distress. The HADS score ranges from 0-21 with higher score indicating more psychological distress.

  8. Caregiver psychological distress (using the Hospital Anxiety and Depression Scale (HADS))

    Time frame: Up to 6 months

    The Hospital Anxiety and Depression Scale (HADS) will be used to caregiver psychological distress. The HADS score range from 0-21 with higher scores indicating worse psychological distress

  9. Caregiver Satisfaction with patient's end of life (EOL) care using the FAMCARE

    Time frame: Up to 6 months

    Nine items from the FAMCARE will be used to assess caregivers' satisfaction with the quality of medical services provided to them and the patient at the end of life. FAMCARE provides rating of quality of death on a scale of 0-10, with higher scores indicating best possible death. FAMCARE also provides a total score ranges 0-24, with higher score indicating better satisfaction with EOL care

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • Medically Home

Registry information

Official study title

Hospital-at-Home Care Model to Optimize End-of-Life (EOL) Care for Patients With Hematologic Malignancies: A Pilot Feasibility Study

Important dates

Study start
2021
Primary completion
2024
Study completion
2025
First posted
Dec 30, 2020
Registry last updated
Jul 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.